MedTrace Logo

Subcutaneous Immunotherapy for Mouse in Adults

NCT02532179 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-03-07

Study results available
· View outcomes & findings →

Summary

This is an open label trial of mouse allergenic extract administered by subcutaneous injection in adults with asthma and mouse sensitivity. The study is designed to evaluate:

* the safety of this therapy when given by injection
* biomarkers of the immune response and
* whether the therapy would be effective in treating allergic asthma.

Conditions

  • Asthma
  • Perennial Allergic Rhinitis

Interventions

BIOLOGICAL

Mouse Allergenic Extract

Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.

Sponsors & Collaborators

  • Inner-City Asthma Consortium

    collaborator NETWORK

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Robert Wood, M.D. · Johns Hopkins Children's Center: Department of Allergy & Immunology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02532179 on ClinicalTrials.gov